Amphastar Pharmaceuticals, Inc.
NMS: AMPHLive Quote
📈 ZcoreAI Score
Our AI model analyzes Amphastar Pharmaceuticals, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get AMPH Z-Score →About Amphastar Pharmaceuticals, Inc.
Healthcare
Drug Manufacturers - Specialty & Generic
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose. The company also provides Cortrosyn, a lyophilized power for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; and emergency syringe products, including atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate. In addition, it offers Albuterol sulfate inhalation aerosol for the treatment or prevention of bronchospasm; Iron sucrose injection, an iron replacement product for the treatment of iron deficiency anemia in patients with chronic kidney disease; Teriparatide injection for managing daily osteoporosis therapy; and Ipratropium Bromide HFA inhalation aerosol, an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease. Further, the company provides active pharmaceutical ingredient (API) products, such as Recombinant Human Insulin and porcine insulin API. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
📊 Fundamental Analysis
Amphastar Pharmaceuticals, Inc. demonstrates a healthy profit margin of 13.6%.
The company recently reported -1.8% revenue growth, which is negative, indicating a recent decline in revenue.
Return on Equity (ROE) is 12.9%, which suggests room for improvement in capital utilization.
At a current price of $20.37, AMPH currently sits at the 23rd percentile of its 52-week range (Range: $17.03 - $31.26).
💰 Valuation Insight
AMPH trades at a 59.9% discount (PE: 10.03), which may represent a value opportunity given the sector average of 25.00. Analysts expect earnings growth, as indicated by a lower forward PE.
🏥 Financial Health
⚠️
Profit Margin
Moderate
🔴
Debt/Equity
Elevated
🔴
Revenue Growth
Weak
🔴
Return on Equity
Weak
⚠️
Beta (Risk)
Moderate Volatility
Key Financials
Market Cap
$936.05M
Trailing P/E
10.03
Forward P/E
5.89
Beta (5Y)
0.91
52W High
$31.26
52W Low
$17.03
Avg Volume
496K
Day High
Day Low